Mindset Pharma Announces Filing of International Patent Application Covering its Family 3 “Microdose” Compounds
Here’s a fun way to bond with grandma…
Mindset Pharma (MSET) filed a patent for psilocybin microdoses that have potential to treat Alzheimer’s disease and ADHD.
The compounds may promote cognitive benefits without the liability of a psychedelic experience, making them suitable for “fragile population groups” like children and the elderly, according to the company’s Chief Scientific Officer.